Oral TYK2 Inhibition in Atopic Dermatitis - Takeaways - MDSpire

Oral TYK2 Inhibition in Atopic Dermatitis

Phase 2 trial evaluated once-daily oral TYK2 inhibition in adults with moderate to severe AD.

  • By

  • Kathryn Wighton

  • February 5, 2026

  • 4 min

Share

  • 1

    The phase 2 trial demonstrated that oral ICP-332 significantly reduced atopic dermatitis severity and pruritus in adults.

  • 2

    At week 4, mean reductions in Eczema Area and Severity Index were 78% for the 80-mg dose and 73% for the 120-mg dose compared to 17% for placebo.

  • 3

    64% of patients receiving ICP-332 achieved an Eczema Area and Severity Index 75 response, compared to 8% with placebo.

  • 4

    Treatment-emergent adverse events occurred in 68% of placebo patients and 76% and 75% of those receiving ICP-332, all classified as mild or moderate.

  • 5

    The study supports further phase 3 trials to confirm ICP-332's efficacy and safety in treating moderate to severe atopic dermatitis.

Original Source(s)

Oral TYK2 Inhibition in Atopic Dermatitis

  • by Kathryn Wighton

  • February 5, 2026

Related Content

MDA5-related juvenile dermatomyositis and interstitial lung disease: Transitioning from rapid progression to a quiescent state in three pediatric cases from South Africa, along with a literature review.

Biologics Commonly Used in Cutaneous Crohn's Disease

Retrospective multicenter cohort highlights genital-predominant presentation patterns and frequent combination therapy use in cutaneous Crohn's disease.

Detecting comorbidity patterns in rare disease patients with machine learning